A phase Ib single-arm study of bintrafusp alfa for the treatment of pretreated, locally advanced/unresectable or metastatic urothelial cancer.

被引：2
|
作者：
Grivas, Petros [1 ]
Morales-Barrera, Rafael [2 ]
Sridhar, Srikala S. [3 ]
Loriot, Yohann [4 ]
Van der Heijden, Michiel Simon [5 ]
Galsky, Matt D. [6 ]
Baxter, Dawn [7 ]
Khaled, Ahmed Hussein [7 ]
Hug, Bruce A. [7 ]
机构：
[1] Univ Washington, Fred Hutchinson Canc Res Ctr, Dept Med, Div Oncol,Seattle Canc Care Alliance, Seattle, WA 98195 USA
[2] Univ Autonoma Barcelona, Vall dHebron Univ Hosp, Vall dHebron Inst Oncol, Barcelona, Spain
[3] Princess Margaret Canc Ctr, Canc Clin Res Unit, Toronto, ON, Canada
[4] Univ Paris Saclay, Inst Gustave Roussy, Dept Canc Med, Villejuif, France
[5] Netherlands Canc Inst, Amsterdam, Netherlands
[6] Icahn Sch Med Mt Sinai, Tisch Canc Inst, Dept Med, Div Hematol Oncol, New York, NY 10029 USA
[7] GlaxoSmithKline, Collegeville, PA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 06期
关键词：
D O I：
10.1200/JCO.2021.39.6_suppl.TPS501
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS501
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Phase I Trial of First-line Bintrafusp Alfa in Patients with Locally Advanced or Persistent/Recurrent/Metastatic Cervical Cancer
    Oaknin, Ana
    Ghamande, Sharad A.
    Kasamatsu, Yuka
    Gil-Martin, Marta
    Grau-Bejar, Juan Francisco
    Garcia-Duran, Carmen
    Sato, Masashi
    Siddiqui, Abdul
    Chaudhary, Surendra Pal
    Vugmeyster, Yulia
    Hasegawa, Kosei
    CLINICAL CANCER RESEARCH, 2024, 30 (05) : 975 - 983
  • [22] Reasons for lack of treatment in patients with locally advanced, unresectable or metastatic urothelial carcinoma
    Omland, Lise H.
    Joensen, Ulla N.
    Toft, Birgitte G.
    Lund, Cecilia M.
    Lindberg, Henriette
    Knudsen, Mark B.
    Tolver, Anders
    Suetta, Charlotte
    Pappot, Helle
    ACTA ONCOLOGICA, 2022, 61 (09) : 1036 - 1042
  • [23] A Single-Arm Phase II Study of Nab-Paclitaxel Plus Gemcitabine and Cisplatin for Locally Advanced or Metastatic Biliary Tract Cancer
    Liu, Ting
    Li, Qing
    Lin, Zhen
    Liu, Chunhua
    Pu, Wei
    Zeng, Shasha
    Lai, Jun
    Cai, Xuebin
    Zhang, Lisha
    Wang, Shuyang
    Chen, Miao
    Cao, Wei
    Gou, Hongfeng
    Zhu, Qing
    CANCER RESEARCH AND TREATMENT, 2024, 56 (02): : 602 - 615
  • [24] A phase Ib study of VEGFR inhibitor fruquintinib in patients with pretreated advanced colorectal cancer.
    Li, Jin
    Cao, Junning
    Xu, Rui-hua
    Chen, Zhiyu
    Zhang, Jian
    Ji, Dongmei
    Zhang, Sheng Dong
    Wang, Fenghua
    Fan, Songhua
    Mu, Hua
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [25] First-Line Treatment of Locally Advanced or Metastatic Pulmonary Lymphoepitheliomalikecarcinoma: A Multicenter, Single-Arm, Phase II Trial
    Zhou, C.
    Lin, X.
    Li, S.
    Sun, N.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S96 - S97
  • [26] Single-arm phase ib/II study of durvalumab and guadecitabine in advanced kidney cancer (NCT03308396).
    Yentz, Sarah Elizabeth
    Reimers, Melissa Andrea
    Joshi, Monika
    Zakharia, Yousef
    Gupta, Shilpa
    Singer, Eric A.
    Daignault, Stephanie
    Zou, Weiping
    Musapatika, Dana
    Alva, Ajjai Shivaram
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [27] Phase I study of TIGIT inhibitor M6223 as monotherapy or in combination with bintrafusp alfa (BA) in patients (pts) with metastatic/locally advanced solid unresectable tumours
    Siu, L. L.
    Mckean, M. A.
    Tolcher, A. W.
    Victor, A.
    Kitzing, T.
    Pierre, V.
    Gleicher, S.
    Holland, D. G.
    Richter, E.
    Naing, A.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S887 - S887
  • [28] SGNLVA-002: Single-arm, open label phase lb/II study of ladiratuzumab vedotin (LV) in combination with pembrolizumab for first-line treatment of patients with unresectable locally advanced or metastatic triple-negative breast cancer.
    Han, Hyo S.
    Alemany, Carlos A.
    Brown-Glaberman, Ursa Abigail
    Pluard, Timothy J.
    Sinha, Rajni
    Sterrenberg, Danielle
    Albain, Kathy S.
    Basho, Reva K.
    Biggs, David
    Boni, Valentina
    Diab, Sami
    Tsai, Michaela L.
    Tkaczuk, Katherine Hanna
    Wang, Yinghui
    Wang, Zejing
    Meisel, Jane Lowe
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [29] Atezolizumab (atezo) therapy for upper tract (UT) urothelial carcinoma (UC): Subgroup analysis of the single-arm international SAUL study in pretreated locally advanced/metastatic urinary tract carcinoma
    Sternberg, Cora N.
    Loriot, Yohann
    Tambaro, Rosa
    Buttigliero, Consuelo
    Morelli, Franco
    Papai, Zsuzsanna
    Retz, Margitta
    Necchi, Andrea
    Van Der Heijden, Michiel Simon
    Faust, Guy
    Zorrilla, Andres Felipe Cardona
    Lainez, Nuria
    Panni, Stefano
    Etxaniz, Olatz
    Krieger, Laurence
    Vidal, Maria Jose Jose Mendez
    Los, Maartje
    de Ducla, Sabine
    Fear, Simon
    Merseburger, Axel Stuart
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [30] A phase 2 single-arm study to assess clinical activity, efficacy and safety of enzalutamide (ENZA) with trastuzumab in HER2+AR+ metastatic or locally advanced breast cancer.
    Trudeau, Maureen E.
    Winer, Eric P.
    Steinberg, Joyce Leta
    Liosatos, Maggie
    Poondru, Srinivasu
    Dydo, Michael Nicholas
    Peterson, Amy C.
    Gradishar, William John
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
12345